Research compounds
Atrial natriuretic peptide
ANP, carperitide, anaritide
Atrial natriuretic peptide is a cardiac hormone released from the atria in response to stretch. A recombinant form, carperitide, is approved in Japan for acute heart failure but not in the United States.
Also known as: carperitide, anaritide, Hanp, atrial natriuretic factor
- Status
- Atrial natriuretic peptide is approved in at least one country outside the U.S. but not approved by the FDA.
- Evidence
- Human trials. Published clinical trials in people report results.
- Half-life
- Approximately 2 to 5 minutes.
- How it's taken
- Continuous intravenous infusion
- Mechanism
- Other
How Atrial natriuretic peptide works
ANP is released when atrial wall stretch signals volume overload. It binds natriuretic peptide receptor A, raising cGMP to produce natriuresis, diuresis, vasodilation and suppression of the renin-angiotensin-aldosterone system — an integrated response that reduces both preload and afterload. It is the physiological counterweight to the renin-angiotensin system.
What research has looked at
- It is the endogenous counter-regulatory hormone to volume overload, and understanding it underpins both natriuretic peptide diagnostics and the neprilysin-inhibitor drug class.
- Carperitide is approved and used in Japan for acute decompensated heart failure.
- The pathway is therapeutically validated indirectly: sacubitril blocks neprilysin, the enzyme that degrades natriuretic peptides, and sacubitril/valsartan improves heart failure outcomes.
Evidence level: Human trials. Published clinical trials in people report results. These are areas studied or reported, not promised effects.
Reported side effects and risks
- It is not approved in the United States, and the closely related nesiritide failed to show outcome benefit in the large ASCEND-HF trial. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- Hypotension is the dominant adverse effect and can be marked and prolonged.
- Its half-life of a few minutes means continuous infusion is required.
- Evidence for carperitide rests substantially on Japanese registry data rather than large randomised outcome trials.
Sources
- PubMed research on atrial natriuretic peptide carperitide heart failure · NIH · National Library of Medicine
- DrugBank record for carperitide · DrugBank
- Active clinical trials for carperitide · U.S. National Library of Medicine
Track Atrial natriuretic peptide in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Atrial natriuretic peptide FAQ
What is Atrial natriuretic peptide?
Atrial natriuretic peptide is a cardiac hormone released from the atria in response to stretch. A recombinant form, carperitide, is approved in Japan for acute heart failure but not in the United States.
How does Atrial natriuretic peptide work?
ANP is released when atrial wall stretch signals volume overload. It binds natriuretic peptide receptor A, raising cGMP to produce natriuresis, diuresis, vasodilation and suppression of the renin-angiotensin-aldosterone system — an integrated response that reduces both preload and afterload. It is the physiological counterweight to the renin-angiotensin system.
Is Atrial natriuretic peptide FDA approved?
No. Atrial natriuretic peptide is approved in at least one country outside the U.S. but not approved by the FDA. Evidence level: human trials. Published clinical trials in people report results.
What is the half-life of Atrial natriuretic peptide?
Reported half-life: Approximately 2 to 5 minutes.
How is Atrial natriuretic peptide taken?
Continuous intravenous infusion.
What side effects have been reported with Atrial natriuretic peptide?
Reported in the sources: It is not approved in the United States, and the closely related nesiritide failed to show outcome benefit in the large ASCEND-HF trial. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; Hypotension is the dominant adverse effect and can be marked and prolonged; Its half-life of a few minutes means continuous infusion is required; Evidence for carperitide rests substantially on Japanese registry data rather than large randomised outcome trials.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.